How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,220 results for

Mean Corpuscular Volume

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

) at the screening visit Transferrin Saturation (TSAT) <16% (any subject) at the screening visit Microcytic, hypochromic anaemia defined as: a) Mean corpuscular Hb concentration (MCHC) <32%; b) Mean corpuscular volume (MCV) < 80 fL; c)Mean corpuscular Hb (MCH) <27 pg Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments Before any study-specific procedure is conducted, the appropriate written informed (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

162. Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia

for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male or female Age equal to or more than 18 years Written informed consent provided by the patient Hb below 10g/dl, as defined by other trials Absolute red blood cell (RBC) count below 4.5 x 106/mm3 for men or 4.0 x 106/mm3 for women Mean corpuscular volume (MCV) of RBCs below 80 fl Mean corpuscular Hb (MCH) of RBCs below 27 pg (...) remove one or more studies before adding more. Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (ACCESS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03524651

2018 Clinical Trials

163. Iron Parameters in Non-anemic First Trimester Gravidas

Task Force (USPSTF) stated "there is insufficient evidence to recommend the routine screening for iron deficiency in non-anemic gravidas". The basis for this recommendation is the lack maternal or fetal outcome data in this population. To date, there are no guidelines for the treatment of non-anemic, iron deficiency pregnancy women with or without anemia. Obstetricians and gynecologists often do not screen for iron deficiency unless the mean corpuscular volume (MCV) is reduced even in the presence (...) Gravidas The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03670537 Recruitment Status : Completed First Posted : September 13, 2018 Results First Posted : October 15, 2018 Last Update Posted : October 15, 2018 Sponsor: Auerbach Hematology Oncology Associates P C Collaborator: MedStar Women's Care

2018 Clinical Trials

164. Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjec

, whether or not considered related to the medicinal product. Number of subjects who will discontinue the treatment due to AEs will be reported. Number of subjects with abnormal hematology findings [ Time Frame: Up to 40 months ] Blood samples will be collected to measure platelets, white blood cell (WBC count), red blood cell (RBC) count, reticulocyte count, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), basophils, eosinophils, lymphocytes, monocytes and neutrophils. Number (...) ) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjects From the LATTE Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03639311 Recruitment

2018 Clinical Trials

165. A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

. Part A- Number of subjects with abnormal hematology parameters [ Time Frame: Up to 12 weeks ] Blood samples will be collected to measure platelets, white blood cell (WBC count), red blood cell (RBC) count, reticulocyte count, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), basophils, eosinophil's, lymphocytes, monocytes and neutrophils. Part A- Number of subjects with abnormal urinalysis [ Time (...) number of saved studies (100). Please remove one or more studies before adding more. A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

166. A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

assessments: Haematology - Mean corpuscular volume (MCV) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration) or discontinuation. ] To assess MCV as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Haematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration (...) ) or discontinuation. ] To assess MCH as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Haematology - Mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration) or discontinuation. ] To assess MCHC as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Haematology - Differential

2018 Clinical Trials

167. Pilates Program in Female Adolescent With Eating Disorders

dispersion; transferrin saturation index. Changes in blood parameters measured in fL. [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameter measured in fL were analyzed: mean corpuscular volume. Changes in blood parameters measured in μg/dL [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameter measured in μg/dL were analyzed: iron. Changes in blood parameters measured in mmol/L. [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood (...) ; hemoglobin; mean corpuscular hemoglobin concentration. Changes in blood parameters measured in 10^3/μL. [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameters measured in 10^3/μL were analyzed: platelets; red blood cells; leukocytes; lymphocytes; neutrophils; monocytes; basophils; eosinophils. Changes in blood parameters measured in % [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameters measured in % were analyzed: hematocrit; red blood cell

2018 Clinical Trials

168. An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

with abnormal findings for hematology parameters [ Time Frame: Up to 28 days ] Blood samples will be collected from subjects for the analysis of hematology parameters as a measure of safety, including platelet count, mean corpuscular volume, mean corpuscular hemoglobin, percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's, basophils, red blood cells count, hemoglobin, and hematocrit coagulation test. Number of subjects with abnormal findings for urinalysis parameters [ Time Frame: Up (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

169. Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

) between the Chronocort arm and Standard Care arm. Safety of Chronocort® compared to standard care by assessment of routine safety haematology assessments - mean corpuscular volume (MCV) [ Time Frame: Baseline (Day 1), Week 2, Week 6, Week 12, Week 26, Week 39 & Week 52 ] Routine haematology assessments to compare mean corpuscular volumes (volume of red blood cells) between the Chronocort arm and Standard Care arm. Safety of Chronocort® compared to standard care by assessment of routine safety (...) before adding more. Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03532022 Recruitment Status : Suspended (Protocol re-design required following inconclusive EU Phase III results) First Posted : May 22

2018 Clinical Trials

170. Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

will be collected for assessment of hematology parameters including platelet count, red blood cell count (RBC), hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, percentage of reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's and basophils. Number of subjects with abnormal hematology parameters: Part B [ Time Frame: Up to 35 days ] Blood samples will be collected for assessment of hematology parameters including platelet count, RBC, hemoglobin, hematocrit, mean (...) corpuscular volume, mean corpuscular hemoglobin, percentage of reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's and basophils. Number of subjects with abnormal clinical chemistry parameters: Part A [ Time Frame: Up to 49 days ] Blood samples will be collected for the assessment of clinical chemistry parameters blood urea nitrogen, creatinine, glucose fasting, potassium, sodium, calcium, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total and direct bilirubin

2018 Clinical Trials

171. A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

to Day 128 in Mean corpuscular volume (MCV) after supplementation with Salmon Protein Hydrolysate Powder (CollaGo®) [ Time Frame: Baseline (Day 0) to end-of-study (Day 128) ] Change from baseline to Day 128 in mean corpuscular hemoglobin (MCH) after supplementation with Salmon Protein Hydrolysate Powder (CollaGo®) [ Time Frame: Baseline (Day 0) to end-of-study (Day 128) ] Change from baseline to Day 128 in mean corpuscular hemoglobin concentration (MCHC) after supplementation with Salmon Protein (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our

2018 Clinical Trials

172. A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma

parameters [ Time Frame: Up to Week 52 ] Hematology parameters which will be assessed include platelet count, red blood cell (RBC) count, hemoglobin, hematocrit; RBC indices: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH); white blood cell (WBC) count with differential: neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Up to Week 52 ] Clinical chemistry parameters which will be assessed include (...) Frame: Up to Week 52 ] An exacerbation is defined as worsening of asthma requiring the use of systemic corticosteroids and/or emergency department visit, or hospitalization. Mean change from Baseline in clinic prebronchodilator forced expiratory volume in 1 second (FEV1) at Week 52 [ Time Frame: Baseline and Week 52 ] FEV1 is the volume of air that can be forced out in one second after taking a deep breath. FEV1 will be measured via spirometer at Baseline and Week 52. Number of subjects with adverse

2018 Clinical Trials

173. Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia

less than 11.0 or hematocrit less than 33% with ferritin 25 ug/L Age 18-64 years old. Gestational age between 12 0/7 weeks and 34 0/7 weeks. No other known causes of anemia (Folate or vit b12 deficiency anemia, sideroblastic anemia, thalassemia, sickle cell anemia, aplastic anemia, hemolytic anemia, anemia of chronic disease). Anemic patients with a low ferritin level and a mean corpuscular volume (MCV) >95 will have folate and vitamin B12 measured since some patients might have combined causes (...) studies before adding more. Daily vs Alternate Day Iron Supplementation for Pregnant Women With Iron Deficiency Anemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03562143 Recruitment Status : Recruiting First Posted

2018 Clinical Trials

174. Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

analytes, platelet counts, red blood cells (RBC) count, white blood cells (WBC) count, hemoglobin, hematocrit, RBC indices (mean corpuscle volume [MCV], mean corpuscle hemoglobin [MCH], and mean corpuscular hemoglobin concentration (MCHC) and differential WBC count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Number of subjects with toxicity grading values values higher than Grade 3 or Grade 4 for hematology, Part 2 [ Time Frame: Up to 15 days ] Blood samples will be collected (...) does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03562117 Recruitment Status : Completed First Posted : June 19, 2018 Last Update Posted : January 25, 2019 Sponsor: GlaxoSmithKline Collaborator: Biomedical Advanced Research and Development Authority Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: This is a two-part study which will evaluate the PK, safety

2018 Clinical Trials

175. Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

] Number of subjects with AE /SAEs leading to pembrolizumab administration delay, interruptions, and withdrawals will be summarized. Number of subjects with abnormal hematology parameters [ Time Frame: Up to 2 years ] Blood samples will be collected for the assessment of the following hematology parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils (...) Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03697824 Recruitment Status : Withdrawn (Internal decision, study will be replaced with a larger monotherapy trial) First Posted : October 5, 2018 Last Update Posted

2018 Clinical Trials

176. Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions

of total Protein. Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points [ Time Frame: Day -1 and Day 2 of each treatment period ] Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of hematology parameters including platelets, neutrophils, monocytes, lymphocytes, leucocyte, eosinophils and basophils. Mean Corpuscular Volume (MCV) at Indicated Time-points [ Time Frame: Day -1 and Day 2 (...) of each treatment period ] Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCV. Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points [ Time Frame: Day -1 and Day 2 of each treatment period ] Blood samples were collected from participants on Day -1 and Day 2 of each treatment period 1 and 2 for evaluation of MCH. Erythrocyte Count at Indicated Time-points [ Time Frame: Day -1 and Day 2 of each treatment period ] Blood samples

2018 Clinical Trials

177. Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

hemoglobin concentration (MCHC) [ Time Frame: From baseline up to follow-up (5 to 7 days post last dose) ] To assess the MCHC as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory assessments: Hematology - Mean corpuscular volume (MCV) [ Time Frame: From baseline up to follow-up (5 to 7 days post last dose) ] To assess the MCV as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory (...) up to follow-up (5 to 7 days post last dose) ] To assess the Hb as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: From baseline up to follow-up (5 to 7 days post last dose) ] To assess the MCH as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Laboratory assessments: Hematology - Mean corpuscular

2018 Clinical Trials

178. Peer Support in Diabetes Management

at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Hemoglobin (g/L) Change from Baseline Red Blood Cell Count at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Red blood cell count (10^12/L) Change from Baseline Mean Corpuscular Volume at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Mean Corpuscular Volume (fL) Change from Baseline Mean Corpuscular Hemoglobin at 6 and 12 months [ Time Frame: Baseline, 6 months, 12 months ] Mean Corpuscular Hemoglobin (...) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03437525 Recruitment Status : Active, not recruiting First Posted : February 19, 2018 Last Update Posted : February 19, 2018 Sponsor: Shanghai 6th People's Hospital Collaborators: University of North Carolina, Chapel Hill Asian Center for Health Education

2018 Clinical Trials

179. A Study to Evaluate the Safety, Tolerability and Study Drug Absorption to the Blood After Administration of Single Ascending Doses of AZD8154 in Healthy Participants.

by assessment of mean cell volume (MCV). Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-mean corpuscular hemoglobin (MCH) [ Time Frame: From baseline up to follow-up visit (6 days post final dose) ] Safety and tolerability of AZD8154 by assessment of mean corpuscular hemoglobin (MCH). Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: From baseline up to follow-up visit (6 (...) and tolerability of AZD8154 by assessment of HCT. Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-platelets [ Time Frame: From baseline up to follow-up visit (6 days post final dose) ] Safety and tolerability of AZD8154 by assessment of platelets. Safety and tolerability of AZD8154 by assessment of clinical Laboratory evaluations-mean cell volume (MCV) [ Time Frame: From baseline up to follow-up visit (6 days post final dose) ] Safety and tolerability of AZD8154

2018 Clinical Trials

180. Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

count, neutrophils, white blood cell count, lymphocytes, hemoglobin, monocytes, hematocrit, eosinophils, mean corpuscular volume, basophils, and mean corpuscular hemoglobin. Number of subjects with abnormal findings for clinical chemistry laboratory parameters through 144 weeks [ Time Frame: Up to 144 weeks ] Blood samples will be collected from subjects for analysis of clinical chemistry parameters including blood urea nitrogen, potassium, aspartate aminotransferase, total bilirubin, creatinine (...) parameters through 96 weeks [ Time Frame: Up to 96 weeks ] Blood samples will be collected from subjects for analysis of hematology parameters including platelet count, red blood cell count, neutrophils, white blood cells, lymphocytes, hemoglobin, monocytes, hematocrit, eosinophils, mean corpuscular volume, basophils, and mean corpuscular hemoglobin. Number of subjects with abnormal findings for clinical chemistry laboratory parameters through 96 weeks [ Time Frame: Up to 96 weeks ] Blood samples

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>